首頁 › 非小細胞肺癌 › 威斯康辛州 › Green Bay
Green Bay, WI 的 非小細胞肺癌 臨床試驗
14 項針對 非小細胞肺癌 的研究正在 Green Bay（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
招募中3 期
- Bellin Memorial Hospital, Green Bay
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Bellin Memorial Hospital, Green Bay
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- 還有 4 項
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- Saint Vincent Hospital Cancer Center at Oconto Falls, Oconto Falls · 距離 25 英里
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
招募中3 期
- HSHS St. Vincent Hospital Regional Cancer Center, Green Bay
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
招募中3 期
- Aurora BayCare Medical Center, Green Bay
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
招募中2 期
- Aurora BayCare Medical Center, Green Bay
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Appleton · 距離 26 英里
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中觀察性研究
- ThedaCare Regional Cancer Center, Appleton · 距離 26 英里
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- Ascension Network - St Elizabeth's Hospital, Appleton · 距離 26 英里
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Aurora BayCare Medical Center, Green Bay
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
招募中2 期
- Aurora BayCare Medical Center, Green Bay
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- Aurora BayCare Medical Center, Green Bay
- 還有 1 項
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Saint Vincent Hospital Cancer Center at Saint Mary's, Green Bay
- Aurora BayCare Medical Center, Green Bay
- 還有 3 項
GEMINI-NSCLC: NSCLC Biomarker Study
招募中觀察性研究
- ThedaCare Regional Cancer Center, Appleton · 距離 26 英里
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Green Bay 的其他研究
- 肺癌12 項研究
- 大腸直腸癌10 項研究
- 急性髓系白血病8 項研究
- 結腸癌8 項研究
- 癌症（所有類型）7 項研究
- 乳癌7 項研究
- 頭頸部鱗狀細胞癌7 項研究
- 胰臟癌6 項研究
- 膀胱癌6 項研究
- 黑色素瘤6 項研究
- 腎臟癌（腎細胞癌）6 項研究
- 前列腺癌6 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。